‘We just need someone who’s not crazy’: How the White House decided on Erica Schwartz for CDC director

White House Selects Erica Schwartz as CDC Director Amid Agency Turmoil

A Search for Stability After Years of Upheaval

We just need someone who s not – Over the past twelve months, the Centers for Disease Control and Prevention has endured considerable challenges. A devastating shooting incident, sudden shifts in leadership, and damage to its reputation as an internationally recognized health organization have all contributed to a period of uncertainty. When the Trump administration began searching for a replacement director, one particular criterion emerged above all others. According to a White House representative speaking to CNN during the extended selection process, the primary goal was straightforward: they needed someone stable and reasonable. This search ultimately led to President Trump choosing Erica Schwartz, a retired Coast Guard officer and former deputy surgeon general, for the position in April.

Schwartz’s confirmation hearing takes place Wednesday before the Senate Health, Education, Labor and Pensions Committee. She will testify alongside Sean Kaufman, who has been nominated by the president to serve as Assistant Secretary of Preparedness and Response. Senior health officials and sources familiar with the selection process told CNN that Schwartz’s appointment was designed to restore order to an agency experiencing nearly continuous disruption. This instability has severely impacted employee morale and undermined public confidence in the administration’s health priorities.

Testing Ground for Public Health Leadership

The necessity for capable CDC leadership has grown even more pressing in recent months. The agency has been managing multiple health crises simultaneously, offering assistance for an Ebola situation in central Africa while working urgently to address a surge in parasitic gastrointestinal illness across numerous states. Schwartz represents a significant shift from previous candidates the administration considered, many of whom aligned closely with the “Make America Healthy Again” movement. She brings extensive experience overseeing vaccination initiatives and managing public health emergencies for the federal government.

This background stands in sharp contrast to Trump’s initial CDC selection, whose nomination was eventually withdrawn after it became apparent that his skepticism regarding vaccines would create obstacles to confirmation. Schwartz’s candidacy has already received positive feedback from members of Congress, leading to optimism within the White House that her confirmation could proceed rapidly. As the administration increases its attention on upcoming midterm elections, this appointment signals a broader effort by Trump’s team to exercise greater control over the Health and Human Services Department, which has been directed by Robert F. Kennedy Jr. and has previously enjoyed considerable freedom to pursue controversial changes to vaccine policies and other fundamental health programs.

Reactions from Multiple Perspectives

The appointment has generated mixed responses from different groups. While some mainstream public health professionals remain uncertain, the decision has already unsettled supporters of the Make America Healthy Again initiative. Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security and spokesperson for the Infectious Diseases Society of America, offered a measured assessment:

“She’s a good and well-qualified nominee, and would be in any administration. However, the issue is not her qualifications — it’s the environment that she’s being asked to work in.”

Dr. Adalja continued by noting that if this selection represents a genuine shift away from recent policies, it might prove superficial if Kennedy remains in his position.

Meanwhile, Toby Rogers, a well-known critic of vaccines, expressed strong disappointment on social media platform X. He characterized Schwartz’s appointment as “a slap in the face to the medical freedom base that gave Trump the presidency in 2016 and 2024.” Rogers went further, suggesting that the White House had essentially abandoned efforts to appeal to midterm voters.

Context of Previous CDC Leadership Changes

The White House has demonstrated clear eagerness to distance the health department from negative publicity before the midterm elections, which could potentially determine Republican control of Congress and influence President Trump’s legislative priorities. Vaccines have consistently been a contentious issue throughout this period. Trump initially withdrew his first choice, former congressman Dr. Dave Weldon, when his positions on vaccines threatened to delay confirmation proceedings.

The CDC director who ultimately received confirmation, Dr. Susan Monarez, a scientist with decades of public health experience, quickly found herself in conflict with Kennedy over vaccine strategies and his attempts to remove certain senior CDC officials. Her tenure lasted less than one month before she was dismissed. Following Monarez’s notable departure last August, certain Trump administration officials wondered whether pursuing another permanent nominee was worthwhile.

Kennedy subsequently appointed his then-deputy secretary, Jim O’Neill, as interim director and moved to centralize decision-making authority among political leaders based in Washington. However, senior White House and HHS officials eventually became dissatisfied with O’Neill, who spent minimal time at the CDC’s Atlanta headquarters and was viewed by political appointees as an inadequate public communicator.

The White House has not yet provided a formal response to requests for comment regarding Schwartz’s appointment. Her confirmation hearing represents a critical moment for the agency as it seeks to rebuild trust and demonstrate effective leadership during a period of significant transition.